Meeting Banner
Abstract #2243

MRS changes in diffuse intrinsic pontine gliomas correlate with survival

Stefan Bluml 1,2 and Ashok Panigrahy 3

1 Children's Hospital Los Angeles/USC, Los Angeles, CA, United States, 2 Rudi Schulte Research Institute, Santa Barbara, CA, United States, 3 Children's Hospital of Pittsburgh/UPMC, Pittsburgh, PA, United States

Diffuse intrinsic pontine glioma (DIPG) carry the worst prognosis in pediatric neurooncology, with the majority of patients dying within six to 18 months after diagnosis. Due to the lack of tissue samples, small patient numbers, and the challenges of clinical research in the pediatric population, there has been no improvement in outcomes for decades. This study demonstrates that serial MRS identifies subgroups of longer survival vs. shorter survival survival at an early stage of the disease. This finding demonstrates that MRS could be used to adjust therapies in individual patients but also to evaluate the effectiveness of new treatment strategies in a timely fashion.

This abstract and the presentation materials are available to members only; a login is required.

Join Here